Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

Eudald Felip; Edurne Garcia-Vidal; Sara Cabrero-de las Heras; Adrià Bernat-Peguera; Beatriz Cirauqui; Milana Bergamino; Vanesa Quiroga; Iris Teruel; Angelica Ferrando-Díez; Anna Pous; Assumpció Lopez-Paradís; Laia Boronat; Marga Romeo; Ricard Mesía; Pedro Luis Fernandez; Bonaventura Clotet; Eva Riveira-Muñoz; Anna Martínez-Cardús; Ester Ballana; Mireia Margelí

doi:10.1002/ctm2.70426

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (8) : e70426 DOI: 10.1002/ctm2.70426

LETTER TO THE JOURNAL

Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer

Eudald Felip ¹^,²^,³^,⁴
, Edurne Garcia-Vidal ²^,³
, Sara Cabrero-de las Heras ²^,³^,⁵
, Adrià Bernat-Peguera ²^,⁴
, Beatriz Cirauqui ¹^,²^,⁴
, Milana Bergamino ¹^,²^,⁴
, Vanesa Quiroga ¹^,²^,⁴
, Iris Teruel ¹^,²^,⁴
, Angelica Ferrando-Díez ¹^,²^,⁴
, Anna Pous ¹^,²^,⁴
, Assumpció Lopez-Paradís ¹^,²^,⁴
, Laia Boronat ¹^,²^,⁴
, Marga Romeo ¹^,²^,⁴
, Ricard Mesía ¹^,²^,⁴
, Pedro Luis Fernandez ²^,⁶
, Bonaventura Clotet ²^,³^,⁷
, Eva Riveira-Muñoz ²^,³
, Anna Martínez-Cardús ¹^,²^,⁴
, Ester Ballana ²^,³^,⁷
, Mireia Margelí ¹^,²^,⁴

Author information +

History +

PDF

Cite this article

Download citation ▾

Eudald Felip, Edurne Garcia-Vidal, Sara Cabrero-de las Heras, Adrià Bernat-Peguera, Beatriz Cirauqui, Milana Bergamino, Vanesa Quiroga, Iris Teruel, Angelica Ferrando-Díez, Anna Pous, Assumpció Lopez-Paradís, Laia Boronat, Marga Romeo, Ricard Mesía, Pedro Luis Fernandez, Bonaventura Clotet, Eva Riveira-Muñoz, Anna Martínez-Cardús, Ester Ballana, Mireia Margelí. Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer. Clinical and Translational Medicine, 2025, 15(8): e70426 DOI:10.1002/ctm2.70426

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4/6 inhibitors' current practice in breast cancer. Cancer Gene Ther. 2024; 31(9): 1283-1291.

[2]	Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12): 1475-1495.

[3]	Álvarez-Fernández M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer Cell. 2020; 37(4): 514-529.

[4]	Wekking D, Leoni VP, Lambertini M, et al. CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: biological and clinical aspects. Cytokine Growth Factor Rev. 2024; 75: 57-64.

[5]	Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24: S26-S35.

[6]	Ma CX, Gao F, Luo J, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017; 23(15): 4055-4065.

[7]	Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci. 2017; 19(1): 89.

[8]	Goel S, Decristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018; 28(11): 911-925.

[9]	Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19(1): 40-50.

[10]	Gao ZH, Li CX, Liu M, Jiang JY. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020; 20(1): 1150.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.